{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:26:07Z","timestamp":1793816767771,"version":"4.6.1"},"reference-count":128,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1016\/j.vaccine.2009.07.103","type":"journal-article","created":{"date-parts":[[2009,10,17]],"date-time":"2009-10-17T04:27:11Z","timestamp":1255753631000},"page":"D73-D79","source":"Crossref","is-referenced-by-count":62,"special_numbering":"S4","title":["Smallpox vaccines for biodefense"],"prefix":"10.1016","volume":"27","author":[{"given":"Richard B.","family":"Kennedy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inna","family":"Ovsyannikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Poland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2009.07.103_bib1","series-title":"Smallpox","author":"Dixon","year":"1962"},{"key":"10.1016\/j.vaccine.2009.07.103_bib2","series-title":"Smallpox and its eradication","author":"Fenner DAH","year":"1988"},{"key":"10.1016\/j.vaccine.2009.07.103_bib3","series-title":"An inquiry into the causes and effects of the variolae vaccinae, a disease discovered in some of the western counties of England, particularly Gloucestershire and known by the name of the cow pox","author":"Jenner","year":"1798"},{"issue":"4","key":"10.1016\/j.vaccine.2009.07.103_bib4","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/146642409611600412","article-title":"The smallpox saga and the origin(s) of vaccination","volume":"116","author":"Cook","year":"1996","journal-title":"J Royal Soc Health"},{"issue":"September\u2013October(5)","key":"10.1016\/j.vaccine.2009.07.103_bib5","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/clinids\/4.5.916","article-title":"A successful eradication campaign. Global eradication of smallpox","volume":"4","author":"Fenner","year":"1982","journal-title":"Rev Infect Dis"},{"issue":"May(10)","key":"10.1016\/j.vaccine.2009.07.103_bib6","doi-asserted-by":"crossref","first-page":"455","DOI":"10.5694\/j.1326-5377.1980.tb135034.x","article-title":"The global eradication of smallpox","volume":"1","author":"Fenner","year":"1980","journal-title":"Med J Aust"},{"issue":"5","key":"10.1016\/j.vaccine.2009.07.103_bib7","first-page":"669","article-title":"An airborne outbreak of smallpox in a German hospital and its significance with respect to other recent outbreaks in Europe","volume":"43","author":"Wehrle","year":"1970","journal-title":"Bull World Health Organ"},{"issue":"May(19)","key":"10.1016\/j.vaccine.2009.07.103_bib8","first-page":"1920","article-title":"Smallpox and smallpox vaccination","volume":"348","author":"Neff","year":"2003","journal-title":"N Engl J Med"},{"issue":"February(9508)","key":"10.1016\/j.vaccine.2009.07.103_bib9","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0140-6736(06)68143-9","article-title":"Smallpox","volume":"367","author":"Moore","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2009.07.103_bib10","series-title":"Pox Americana: the great smallpox epidemic of 1775\u201382","author":"Fenn","year":"2001"},{"issue":"9","key":"10.1016\/j.vaccine.2009.07.103_bib11","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/nm917","article-title":"Duration of antiviral immunity after smallpox vaccination","volume":"9","author":"Hammarlund","year":"2003","journal-title":"Nat Med"},{"issue":"November(10)","key":"10.1016\/j.vaccine.2009.07.103_bib12","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.4049\/jimmunol.171.10.4969","article-title":"Cutting edge: long-term B cell memory in humans after smallpox vaccination","volume":"171","author":"Crotty","year":"2003","journal-title":"J Immunol"},{"issue":"June(11)","key":"10.1016\/j.vaccine.2009.07.103_bib13","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1084\/jem.20032083","article-title":"Distinct time effects of vaccination on long-term proliferative and IFN-gamma-producing T cell memory to smallpox in humans","volume":"199","author":"Combadiere","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2009.07.103_bib14","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.0105-2896.2006.00392.x","article-title":"Immunity and immunological memory following smallpox vaccination","volume":"211","author":"Amanna","year":"2006","journal-title":"Immunol Rev"},{"issue":"June(24)","key":"10.1016\/j.vaccine.2009.07.103_bib15","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1001\/jama.289.24.3295","article-title":"Response to smallpox vaccine in persons immunized in the distant past","volume":"289","author":"Frey","year":"2003","journal-title":"JAMA"},{"issue":"August(33)","key":"10.1016\/j.vaccine.2009.07.103_bib16","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1016\/j.vaccine.2007.05.044","article-title":"Detailed kinetics of immune responses to a new cell culture-derived smallpox vaccine in vaccinia-naive adults","volume":"25","author":"Kim","year":"2007","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2009.07.103_bib17","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.amjmed.2008.08.019","article-title":"Immunity from smallpox vaccine persists for decades: a longitudinal study","volume":"121","author":"Taub","year":"2008","journal-title":"Am J Med"},{"issue":"March(14)","key":"10.1016\/j.vaccine.2009.07.103_bib18","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.vaccine.2007.12.059","article-title":"Short- and long-term immunogenicity and protection induced by non-replicating smallpox vaccine candidates in mice and comparison with the traditional 1st generation vaccine","volume":"26","author":"Ferrier-Rembert","year":"2008","journal-title":"Vaccine"},{"issue":"September(6)","key":"10.1016\/j.vaccine.2009.07.103_bib19","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1086\/422999","article-title":"Clinical efficacy of intramuscular vaccinia immune globulin: a literature review","volume":"39","author":"Hopkins","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2009.07.103_bib20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1086\/315190","article-title":"Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge","volume":"181","author":"Bray","year":"2000","journal-title":"J Infect Dis"},{"issue":"January(2)","key":"10.1016\/j.vaccine.2009.07.103_bib21","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.virol.2003.11.015","article-title":"Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model","volume":"318","author":"Buller","year":"2004","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.vaccine.2009.07.103_bib22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0166-3542(01)00159-0","article-title":"Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice","volume":"52","author":"Smee","year":"2001","journal-title":"Antiviral Res"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2009.07.103_bib23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0166-3542(02)00195-X","article-title":"Smallpox: a potential agent of bioterrorism","volume":"57","author":"Whitley","year":"2003","journal-title":"Antiviral Res"},{"issue":"August(5)","key":"10.1016\/j.vaccine.2009.07.103_bib24","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/jama.278.5.387","article-title":"Production and use of biological weapons: need for international sanctions?","volume":"278","author":"Leitenberg","year":"1997","journal-title":"JAMA"},{"issue":"13","key":"10.1016\/j.vaccine.2009.07.103_bib25","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1096\/fj.05-1102ufm","article-title":"Biological weapons and secrecy (WC 2300)","volume":"19","author":"Guillemin","year":"2005","journal-title":"Faseb J"},{"issue":"February(5406)","key":"10.1016\/j.vaccine.2009.07.103_bib26","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1126\/science.283.5406.1279","article-title":"The looming threat of bioterrorism","volume":"283","author":"Henderson","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2009.07.103_bib27","series-title":"Smallpox and its eradication","author":"Fenner","year":"1988"},{"issue":"2","key":"10.1016\/j.vaccine.2009.07.103_bib28","doi-asserted-by":"crossref","first-page":"214","DOI":"10.4269\/ajtmh.1972.21.214","article-title":"A prospective study of serum antibody and protection against smallpox","volume":"21","author":"Mack","year":"1972","journal-title":"Am J Trop Med Hyg"},{"issue":"3","key":"10.1016\/j.vaccine.2009.07.103_bib29","first-page":"307","article-title":"The minimum protective level of antibodies in smallpox","volume":"52","author":"Sarkar","year":"1975","journal-title":"Bull World Health Organ"},{"issue":"April(3)","key":"10.1016\/j.vaccine.2009.07.103_bib30","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1001\/jama.212.3.441","article-title":"Deaths attributable to smallpox vaccination, 1959 to 1966, and 1968","volume":"212","author":"Lane","year":"1970","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.vaccine.2009.07.103_bib31","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/infdis\/122.4.303","article-title":"Complications of smallpox vaccination, 1968: results of ten statewide surveys","volume":"122","author":"Lane","year":"1970","journal-title":"J Infect Dis"},{"issue":"June(24)","key":"10.1016\/j.vaccine.2009.07.103_bib32","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.1001\/jama.289.24.3283","article-title":"Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel","volume":"289","author":"Halsell","year":"2003","journal-title":"JAMA"},{"issue":"July(2)","key":"10.1016\/j.vaccine.2009.07.103_bib33","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1086\/375825","article-title":"Smallpox vaccination: a review. Part II. Adverse events","volume":"37","author":"Fulginiti","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2009.07.103_bib34","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S1473-3099(05)70242-5","article-title":"Smallpox vaccine and its stockpile in 2005","volume":"5","author":"Arita","year":"2005","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2009.07.103_bib35","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1089\/bsp.2005.3.256","article-title":"Navigating the storm: report and recommendations from the Atlantic Storm exercise","volume":"3","author":"Smith","year":"2005","journal-title":"Biosecur Bioterror"},{"issue":"March(Suppl. 3)","key":"10.1016\/j.vaccine.2009.07.103_bib36","doi-asserted-by":"crossref","first-page":"S258","DOI":"10.1086\/524749","article-title":"Monitoring the safety of a smallpox vaccination program in the United States: report of the joint Smallpox Vaccine Safety Working Group of the advisory committee on immunization practices and the Armed Forces Epidemiological Board","volume":"46","author":"Neff","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"17\u201318","key":"10.1016\/j.vaccine.2009.07.103_bib37","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/j.vaccine.2005.01.012","article-title":"The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program","volume":"March(23)","author":"Poland","year":"2005","journal-title":"Vaccine"},{"issue":"November\u2013December(6)","key":"10.1016\/j.vaccine.2009.07.103_bib38","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3201\/eid0706.010602","article-title":"Developing new smallpox vaccines","volume":"7","author":"Rosenthal","year":"2001","journal-title":"Emerg Infect Dis"},{"issue":"April(17)","key":"10.1016\/j.vaccine.2009.07.103_bib39","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa020534","article-title":"Clinical responses to undiluted and diluted smallpox vaccine","volume":"346","author":"Frey","year":"2002","journal-title":"N Engl J Med"},{"issue":"September(10)","key":"10.1016\/j.vaccine.2009.07.103_bib40","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1001\/jama.292.10.1205","article-title":"Vaccination success rate and reaction profile with diluted and undiluted smallpox vaccine: a randomized controlled trial","volume":"292","author":"Talbot","year":"2004","journal-title":"JAMA"},{"issue":"July(27\u201328)","key":"10.1016\/j.vaccine.2009.07.103_bib41","first-page":"392","article-title":"Clinical and immune response to undiluted and diluted smallpox vaccine","volume":"138","author":"Gassmann","year":"2008","journal-title":"Swiss Med Wkly"},{"issue":"March(6)","key":"10.1016\/j.vaccine.2009.07.103_bib42","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1086\/511828","article-title":"Reducing the dose of smallpox vaccine reduces vaccine-associated morbidity without reducing vaccination success rates or immune responses","volume":"195","author":"Couch","year":"2007","journal-title":"J Infect Dis"},{"issue":"January(4)","key":"10.1016\/j.vaccine.2009.07.103_bib43","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.vaccine.2005.07.082","article-title":"Clinical and immunological responses to undiluted and diluted smallpox vaccine with vaccinia virus of Lister strain","volume":"24","author":"Hsieh","year":"2006","journal-title":"Vaccine"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2009.07.103_bib44","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S1201-9712(04)00132-8","article-title":"Policies in place throughout the world: action by the European Union","volume":"8","author":"Gouvras","year":"2004","journal-title":"Int J Infect Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2009.07.103_bib45","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/S1201-9712(04)00134-1","article-title":"ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)\u2014a second-generation smallpox vaccine for biological defense","volume":"8","author":"Monath","year":"2004","journal-title":"Int J Infect Dis"},{"issue":"December(52)","key":"10.1016\/j.vaccine.2009.07.103_bib46","doi-asserted-by":"crossref","first-page":"8807","DOI":"10.1016\/j.vaccine.2007.10.040","article-title":"Genomic differences of Vaccinia virus clones from Dryvax smallpox vaccine: the Dryvax-like ACAM2000 and the mouse neurovirulent Clone-3","volume":"25","author":"Osborne","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.07.103_bib47","article-title":"Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax((R)) in healthy vaccinia-naive adults","volume":"December","author":"Frey","year":"2008","journal-title":"Vaccine"},{"issue":"May(25)","key":"10.1016\/j.vaccine.2009.07.103_bib48","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1016\/j.vaccine.2005.01.079","article-title":"A novel, cell culture-derived smallpox vaccine in vaccinia-naive adults","volume":"23","author":"Artenstein","year":"2005","journal-title":"Vaccine"},{"issue":"January(4)","key":"10.1016\/j.vaccine.2009.07.103_bib49","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.vaccine.2007.10.063","article-title":"Clonal vaccinia virus grown in cell culture fully protects monkeys from lethal monkeypox challenge","volume":"26","author":"Marriott","year":"2008","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2009.07.103_bib50","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1517\/13543784.17.4.555","article-title":"ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine","volume":"17","author":"Greenberg","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.vaccine.2009.07.103_bib51","doi-asserted-by":"crossref","unstructured":"Metzger W, Mordmueller BG. Vaccines for preventing smallpox. Cochrane database of systematic reviews (online) 2007(3):CD004913.","DOI":"10.1002\/14651858.CD004913.pub2"},{"issue":"6","key":"10.1016\/j.vaccine.2009.07.103_bib52","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.jaci.2006.09.037","article-title":"Smallpox vaccines: past, present, and future","volume":"118","author":"Parrino","year":"2006","journal-title":"J Allergy Clin Immunol"},{"issue":"January\u2013February(9457)","key":"10.1016\/j.vaccine.2009.07.103_bib53","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0140-6736(05)17840-4","article-title":"Smallpox vaccines: from first to second to third generation","volume":"365","author":"Poland","year":"2005","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.vaccine.2009.07.103_bib54","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1586\/14760584.7.8.1225","article-title":"Smallpox vaccines for biodefense: need and feasibility","volume":"7","author":"Artenstein","year":"2008","journal-title":"Expert Rev Vaccines"},{"issue":"7","key":"10.1016\/j.vaccine.2009.07.103_bib55","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3201\/eid1107.050277","article-title":"Adventitious agents and smallpox vaccine in strategic national stockpile","volume":"11","author":"Murphy","year":"2005","journal-title":"Emerg Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2009.07.103_bib56","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/nm916","article-title":"Clonal vaccinia virus grown in cell culture as a new smallpox vaccine","volume":"9","author":"Weltzin","year":"2003","journal-title":"Nat Med"},{"issue":"January\u2013February(9457)","key":"10.1016\/j.vaccine.2009.07.103_bib57","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S0140-6736(05)70234-8","article-title":"Safety and immunogenicity of new cell-cultured smallpox vaccine compared with calf-lymph derived vaccine: a blind, single-centre, randomised controlled trial","volume":"365","author":"Greenberg","year":"2005","journal-title":"Lancet"},{"issue":"January(6)","key":"10.1016\/j.vaccine.2009.07.103_bib58","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.vaccine.2006.09.046","article-title":"An update on smallpox vaccine candidates and their role in bioterrorism related vaccination strategies","volume":"25","author":"Wiser","year":"2007","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2009.07.103_bib59","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/0264-410X(94)90215-1","article-title":"Characteristics of an attenuated vaccinia virus strain, LC16m0, and its recombinant virus vaccines","volume":"12","author":"Sugimoto","year":"1994","journal-title":"Vaccine"},{"issue":"March(11)","key":"10.1016\/j.vaccine.2009.07.103_bib60","doi-asserted-by":"crossref","first-page":"4152","DOI":"10.1073\/pnas.0406671102","article-title":"Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8","volume":"102","author":"Kidokoro","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"April(17)","key":"10.1016\/j.vaccine.2009.07.103_bib61","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1016\/j.vaccine.2005.03.029","article-title":"Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge","volume":"24","author":"Empig","year":"2006","journal-title":"Vaccine"},{"issue":"5\u20136","key":"10.1016\/j.vaccine.2009.07.103_bib62","first-page":"375","article-title":"The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)","volume":"167","author":"Mayr","year":"1978","journal-title":"Zentralbl Bakteriol [B]"},{"issue":"9","key":"10.1016\/j.vaccine.2009.07.103_bib63","first-page":"322","article-title":"Historical review of smallpox, the eradication of smallpox and the attenuated smallpox MVA vaccine","volume":"112","author":"Mayr","year":"1999","journal-title":"Berl Munch Tierarztl Wochenschr"},{"issue":"March(12)","key":"10.1016\/j.vaccine.2009.07.103_bib64","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.vaccine.2005.11.022","article-title":"Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine","volume":"24","author":"Vollmar","year":"2006","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2009.07.103_bib65","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/14760584.8.1.13","article-title":"IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine","volume":"8","author":"Kennedy","year":"2009","journal-title":"Expert Rev Vaccines"},{"issue":"February(8)","key":"10.1016\/j.vaccine.2009.07.103_bib66","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.vaccine.2006.10.047","article-title":"Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naive and vaccinia-immune individuals","volume":"25","author":"Parrino","year":"2007","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2009.07.103_bib67","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0042-6822(92)90752-B","article-title":"NYVAC: a highly attenuated strain of vaccinia virus","volume":"188","author":"Tartaglia","year":"1992","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2009.07.103_bib68","first-page":"125","article-title":"Safety and immunogenicity of recombinants based on the genetically-engineered vaccinia strain, NYVAC","volume":"82","author":"Tartaglia","year":"1994","journal-title":"Dev Biol Stand"},{"issue":"Pt 12","key":"10.1016\/j.vaccine.2009.07.103_bib69","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1099\/vir.0.2008\/004440-0","article-title":"Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax","volume":"89","author":"Midgley","year":"2008","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2009.07.103_bib70","first-page":"65","article-title":"Safe and effective poxvirus vectors\u2014NYVAC and ALVAC","volume":"82","author":"Paoletti","year":"1994","journal-title":"Dev Biol Stand"},{"issue":"October(8)","key":"10.1016\/j.vaccine.2009.07.103_bib71","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1086\/378518","article-title":"Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques","volume":"188","author":"Edghill-Smith","year":"2003","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2009.07.103_bib72","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1128\/JVI.73.6.4536-4542.1999","article-title":"Highly efficient induction of protective immunity by a vaccinia virus vector defective in late gene expression","volume":"73","author":"Holzer","year":"1999","journal-title":"J Virol"},{"issue":"15","key":"10.1016\/j.vaccine.2009.07.103_bib73","doi-asserted-by":"crossref","first-page":"7713","DOI":"10.1128\/JVI.76.15.7713-7723.2002","article-title":"Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara","volume":"76","author":"Ober","year":"2002","journal-title":"J Virol"},{"issue":"October(1)","key":"10.1016\/j.vaccine.2009.07.103_bib74","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.virol.2005.06.043","article-title":"The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection","volume":"341","author":"Coulibaly","year":"2005","journal-title":"Virology"},{"issue":"4","key":"10.1016\/j.vaccine.2009.07.103_bib75","doi-asserted-by":"crossref","first-page":"215","DOI":"10.7883\/yoken1952.27.215","article-title":"Supplement to the pathogenicity and immunogenicity of an attenuated vaccinia virus, strain DIs, in cynomolgus monkeys","volume":"27","author":"Tagaya","year":"1974","journal-title":"Jap J Med Sci Biol"},{"issue":"4","key":"10.1016\/j.vaccine.2009.07.103_bib76","doi-asserted-by":"crossref","first-page":"245","DOI":"10.7883\/yoken1952.27.245","article-title":"Improved plaque assay of a mutant of vaccinia virus, strain DIs, in chick embryo cell cultures","volume":"27","author":"Tagaya","year":"1974","journal-title":"Jap J Med Sci Biol"},{"issue":"October(2)","key":"10.1016\/j.vaccine.2009.07.103_bib77","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1006\/viro.2002.1622","article-title":"Structural analysis of vaccinia virus DIs strain: application as a new replication-deficient viral vector","volume":"302","author":"Ishii","year":"2002","journal-title":"Virology"},{"issue":"12","key":"10.1016\/j.vaccine.2009.07.103_bib78","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/j.1348-0421.2006.tb03867.x","article-title":"Recombinant vaccinia DIs expressing simian immunodeficiency virus gag and pol in mammalian cells induces efficient cellular immunity as a safe immunodeficiency virus vaccine candidate","volume":"50","author":"Okamura","year":"2006","journal-title":"Microbiol Immunol"},{"issue":"20","key":"10.1016\/j.vaccine.2009.07.103_bib79","doi-asserted-by":"crossref","first-page":"12871","DOI":"10.1128\/JVI.79.20.12871-12879.2005","article-title":"Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guerin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity","volume":"79","author":"Ami","year":"2005","journal-title":"J Virol"},{"issue":"August(1)","key":"10.1016\/j.vaccine.2009.07.103_bib80","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.bbrc.2006.06.086","article-title":"Mechanisms of establishment of persistent SARS-CoV-infected cells","volume":"347","author":"Mizutani","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"issue":"October\u2013November(6040)","key":"10.1016\/j.vaccine.2009.07.103_bib81","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/317813a0","article-title":"Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype","volume":"317","author":"Buller","year":"1985","journal-title":"Nature"},{"issue":"January(5)","key":"10.1016\/j.vaccine.2009.07.103_bib82","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.vaccine.2007.11.045","article-title":"Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: intra-nasal vaccination","volume":"26","author":"Vijaysri","year":"2008","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2009.07.103_bib83","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1073\/pnas.86.4.1287","article-title":"Highly attenuated vaccinia virus mutants for the generation of safe recombinant viruses","volume":"86","author":"Rodriguez","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.vaccine.2009.07.103_bib84","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1128\/JVI.75.1.11-18.2001","article-title":"Vaccinia virus vectors with an inactivated gamma interferon receptor homolog gene (B8R) are attenuated In vivo without a concomitant reduction in immunogenicity","volume":"75","author":"Verardi","year":"2001","journal-title":"J Virol"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2009.07.103_bib85","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jviromet.2007.03.012","article-title":"The attenuation of vaccinia Tian Tan strain by the removal of the viral M1L-K2L genes","volume":"144","author":"Zhu","year":"2007","journal-title":"J Virol Methods"},{"issue":"6","key":"10.1016\/j.vaccine.2009.07.103_bib86","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1128\/JVI.78.6.2770-2779.2004","article-title":"Induction of potent humoral and cell-mediated immune responses by attenuated vaccinia virus vectors with deleted serpin genes","volume":"78","author":"Legrand","year":"2004","journal-title":"J Virol"},{"issue":"September(39)","key":"10.1016\/j.vaccine.2009.07.103_bib87","doi-asserted-by":"crossref","first-page":"5062","DOI":"10.1016\/j.vaccine.2008.06.011","article-title":"Pathogenicity and immunogenicity of recombinant Tiantan Vaccinia Virus with deleted C12L and A53R genes","volume":"26","author":"Dai","year":"2008","journal-title":"Vaccine"},{"issue":"18","key":"10.1016\/j.vaccine.2009.07.103_bib88","doi-asserted-by":"crossref","first-page":"9960","DOI":"10.1128\/JVI.77.18.9960-9968.2003","article-title":"Vaccinia virus interleukin-18-binding protein promotes virulence by reducing gamma interferon production and natural killer and T-cell activity","volume":"77","author":"Reading","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2009.07.103_bib89","article-title":"Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain","volume":"June","author":"Suter","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.07.103_bib90","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1139\/m61-019","article-title":"Loss of immunogenic properties of vaccinia virus inactivated by formaldehyde","volume":"7","author":"Amies","year":"1961","journal-title":"Can J Microbiol"},{"issue":"2","key":"10.1016\/j.vaccine.2009.07.103_bib91","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1017\/S0022172400028679","article-title":"Inactivated smallpox vaccine. A comparison of inactivation methods","volume":"68","author":"Turner","year":"1970","journal-title":"J Hyg (Lond)"},{"issue":"1","key":"10.1016\/j.vaccine.2009.07.103_bib92","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1017\/S0022172400040973","article-title":"The immunogenicity of heat-inactivated vaccinia virus in rabbits","volume":"66","author":"Madeley","year":"1968","journal-title":"J Hyg (Lond)"},{"issue":"6","key":"10.1016\/j.vaccine.2009.07.103_bib93","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/oxfordjournals.aje.a121360","article-title":"The nature of the immune state produced by inactivated vaccinia virus in rabbits","volume":"94","author":"Boulter","year":"1971","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1016\/j.vaccine.2009.07.103_bib94","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1099\/0022-1317-13-1-9","article-title":"An antigenic difference between intracellular and extracellular rabbitpox virus","volume":"13","author":"Appleyard","year":"1971","journal-title":"J Gen Virol"},{"issue":"January(1)","key":"10.1016\/j.vaccine.2009.07.103_bib95","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.virol.2005.09.037","article-title":"Poxvirus entry and membrane fusion","volume":"344","author":"Moss","year":"2006","journal-title":"Virology"},{"issue":"Pt 12","key":"10.1016\/j.vaccine.2009.07.103_bib96","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1099\/0022-1317-83-12-2915","article-title":"The formation and function of extracellular enveloped vaccinia virus","volume":"83","author":"Smith","year":"2002","journal-title":"J Gen Virol"},{"issue":"February(1)","key":"10.1016\/j.vaccine.2009.07.103_bib97","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1006\/viro.1998.9516","article-title":"Neutralizing and protective antibodies directed against vaccinia virus envelope antigens","volume":"254","author":"Galmiche","year":"1999","journal-title":"Virology"},{"issue":"18","key":"10.1016\/j.vaccine.2009.07.103_bib98","doi-asserted-by":"crossref","first-page":"11724","DOI":"10.1128\/JVI.79.18.11724-11733.2005","article-title":"Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice","volume":"79","author":"Davies","year":"2005","journal-title":"J Virol"},{"issue":"January(2)","key":"10.1016\/j.vaccine.2009.07.103_bib99","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1006\/viro.1999.0096","article-title":"DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge","volume":"266","author":"Hooper","year":"2000","journal-title":"Virology"},{"issue":"August(1)","key":"10.1016\/j.vaccine.2009.07.103_bib100","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1006\/viro.1995.1378","article-title":"A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies","volume":"211","author":"Wolffe","year":"1995","journal-title":"Virology"},{"issue":"9","key":"10.1016\/j.vaccine.2009.07.103_bib101","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1128\/JVI.78.9.4433-4443.2004","article-title":"Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox","volume":"78","author":"Hooper","year":"2004","journal-title":"J Virol"},{"issue":"June(9)","key":"10.1016\/j.vaccine.2009.07.103_bib102","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.addr.2005.01.012","article-title":"The role of particle-mediated DNA vaccines in biodefense preparedness","volume":"57","author":"Dean","year":"2005","journal-title":"Adv Drug Deliv Rev"},{"issue":"19","key":"10.1016\/j.vaccine.2009.07.103_bib103","doi-asserted-by":"crossref","first-page":"10230","DOI":"10.1128\/JVI.78.19.10230-10237.2004","article-title":"Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions","volume":"78","author":"Fogg","year":"2004","journal-title":"J Virol"},{"issue":"January(7)","key":"10.1016\/j.vaccine.2009.07.103_bib104","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.vaccine.2006.10.009","article-title":"A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost","volume":"25","author":"Xiao","year":"2007","journal-title":"Vaccine"},{"issue":"February(1)","key":"10.1016\/j.vaccine.2009.07.103_bib105","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0042-6822(02)00038-7","article-title":"Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates","volume":"306","author":"Hooper","year":"2003","journal-title":"Virology"},{"issue":"August(4)","key":"10.1016\/j.vaccine.2009.07.103_bib106","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.4049\/jimmunol.177.4.2552","article-title":"Subunit recombinant vaccine protects against monkeypox","volume":"177","author":"Heraud","year":"2006","journal-title":"J Immunol"},{"issue":"July(1)","key":"10.1016\/j.vaccine.2009.07.103_bib107","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.virol.2008.04.003","article-title":"Heterogeneity in the A33 protein impacts the cross-protective efficacy of a candidate smallpox DNA vaccine","volume":"377","author":"Golden","year":"2008","journal-title":"Virology"},{"issue":"15","key":"10.1016\/j.vaccine.2009.07.103_bib108","doi-asserted-by":"crossref","first-page":"8131","DOI":"10.1128\/JVI.00374-07","article-title":"Major neutralizing sites on vaccinia virus glycoprotein B5 are exposed differently on variola virus ortholog B6","volume":"81","author":"Aldaz-Carroll","year":"2007","journal-title":"J Virol"},{"issue":"February(1)","key":"10.1016\/j.vaccine.2009.07.103_bib109","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.virol.2007.09.029","article-title":"Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigens","volume":"371","author":"Sakhatskyy","year":"2008","journal-title":"Virology"},{"issue":"January(1)","key":"10.1016\/j.vaccine.2009.07.103_bib110","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1084\/jem.20041912","article-title":"Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines","volume":"201","author":"Tscharke","year":"2005","journal-title":"J Exp Med"},{"issue":"February(4)","key":"10.1016\/j.vaccine.2009.07.103_bib111","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.4049\/jimmunol.174.4.2212","article-title":"Identification of murine poxvirus-specific CD8+ CTL epitopes with distinct functional profiles","volume":"174","author":"Mathew","year":"2005","journal-title":"J Immunol"},{"issue":"May(10)","key":"10.1016\/j.vaccine.2009.07.103_bib112","doi-asserted-by":"crossref","first-page":"6374","DOI":"10.4049\/jimmunol.178.10.6374","article-title":"Dominance and diversity in the primary human CD4 T cell response to replication-competent vaccinia virus","volume":"178","author":"Jing","year":"2007","journal-title":"J Immunol"},{"issue":"December(11)","key":"10.1016\/j.vaccine.2009.07.103_bib113","doi-asserted-by":"crossref","first-page":"7550","DOI":"10.4049\/jimmunol.175.11.7550","article-title":"Diversity in the acute CD8 T cell response to vaccinia virus in humans","volume":"175","author":"Jing","year":"2005","journal-title":"J Immunol"},{"issue":"13","key":"10.1016\/j.vaccine.2009.07.103_bib114","doi-asserted-by":"crossref","first-page":"7052","DOI":"10.1128\/JVI.78.13.7052-7060.2004","article-title":"Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses","volume":"78","author":"Snyder","year":"2004","journal-title":"J Virol"},{"issue":"March\u2013April(2)","key":"10.1016\/j.vaccine.2009.07.103_bib115","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/rmv.527","article-title":"T-Cell epitope discovery for variola and vaccinia viruses","volume":"17","author":"Kennedy","year":"2007","journal-title":"Rev Med Virol"},{"issue":"11","key":"10.1016\/j.vaccine.2009.07.103_bib116","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.jasms.2005.07.015","article-title":"Accurate mass precursor ion data and tandem mass spectrometry identify a class I human leukocyte antigen A*0201-presented peptide originating from vaccinia virus","volume":"16","author":"Johnson","year":"2005","journal-title":"J Am Soc Mass Spectrom"},{"issue":"6","key":"10.1016\/j.vaccine.2009.07.103_bib117","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/sj.clpt.6100389","article-title":"Mass spectrometry and peptide-based vaccine development","volume":"82","author":"Ovsyannikova","year":"2007","journal-title":"Clin Pharmacol Therapeut"},{"key":"10.1016\/j.vaccine.2009.07.103_bib118","article-title":"In silico-accelerated identification of conserved and immunogenic variola\/vaccinia T-cell epitopes","volume":"June","author":"Moise","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.07.103_bib119","first-page":"153","article-title":"Recombinant subunit vaccines: potentials and constraints","volume":"121","author":"Clark","year":"2005","journal-title":"Develop Biol"},{"issue":"2","key":"10.1016\/j.vaccine.2009.07.103_bib120","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1128\/CVI.00440-07","article-title":"A novel, killed-virus nasal vaccinia virus vaccine","volume":"15","author":"Bielinska","year":"2008","journal-title":"Clin Vaccine Immunol"},{"issue":"April(16)","key":"10.1016\/j.vaccine.2009.07.103_bib121","doi-asserted-by":"crossref","first-page":"6864","DOI":"10.1073\/pnas.0701451104","article-title":"Smallpox subunit vaccine produced in Planta confers protection in mice","volume":"104","author":"Golovkin","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"October(42)","key":"10.1016\/j.vaccine.2009.07.103_bib122","doi-asserted-by":"crossref","first-page":"15196","DOI":"10.1073\/pnas.0405954101","article-title":"Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox","volume":"101","author":"Jahrling","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"July(2)","key":"10.1016\/j.vaccine.2009.07.103_bib123","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1086\/518800","article-title":"Genetic predisposition for adverse events after vaccination","volume":"196","author":"Crowe","year":"2007","journal-title":"J Infect Dis"},{"issue":"July(2)","key":"10.1016\/j.vaccine.2009.07.103_bib124","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1086\/518794","article-title":"The immunogenetics of smallpox vaccination","volume":"196","author":"Stanley","year":"2007","journal-title":"J Infect Dis"},{"issue":"May(25\u201326)","key":"10.1016\/j.vaccine.2009.07.103_bib125","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1016\/j.vaccine.2009.01.086","article-title":"Gender effects on humoral immune responses to smallpox vaccine","volume":"27","author":"Kennedy","year":"2009","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2009.07.103_bib126","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/sj.clpt.6100379","article-title":"Pharmacology, vaccinomics, and the second golden age of vaccinology","volume":"82","author":"Poland","year":"2007","journal-title":"Clin Pharmacol Therapeut"},{"issue":"November(2)","key":"10.1016\/j.vaccine.2009.07.103_bib127","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.virol.2006.07.017","article-title":"Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen","volume":"355","author":"Sakhatskyy","year":"2006","journal-title":"Virology"},{"issue":"September(25\u201326)","key":"10.1016\/j.vaccine.2009.07.103_bib128","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1016\/j.vaccine.2004.02.034","article-title":"Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB\/c mice from a lethal intranasal poxvirus challenge","volume":"22","author":"Pulford","year":"2004","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09011384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09011384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T23:20:18Z","timestamp":1590189618000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X09011384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":128,"alternative-id":["S0264410X09011384"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2009.07.103","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}